NCT06807463 - A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 15, 2026

Study Completion Date

September 14, 2027

Conditions

Celiac Disease

Interventions

DRUG

TEV-53408

Solution for subcutaneous (sc) injection

DRUG

Placebo

Solution for subcutaneous (sc) injection

Trial Locations (16)

3065

RECRUITING

Teva Investigational Site 78139, Fitzroy

24502

RECRUITING

Teva Investigational Site 12123, Lynchburg

27103

RECRUITING

Teva Investigational Site 12127, Winston-Salem

27834

RECRUITING

Teva Investigational Site 12125, Greenville

30328

RECRUITING

Teva Investigational Site 12130, Atlanta

33016

RECRUITING

Teva Investigational Site 12126, Miami Lakes

33520

RECRUITING

Teva Investigational Site 40062, Tampere

34452

RECRUITING

Teva Investigational Site 12134, Inverness

34653

RECRUITING

Teva Investigational Site 12135, New Port Richey

48038

RECRUITING

Teva Investigational Site 12132, Clinton Township

49519

RECRUITING

Teva Investigational Site 12121, Wyoming

70072

RECRUITING

Teva Investigational Site 12133, Marrero

76712

RECRUITING

Teva Investigational Site 12137, Waco

80907

RECRUITING

Teva Investigational Site 12131, Colorado Springs

84405

RECRUITING

Teva Investigational Site 12122, Ogden

00180

RECRUITING

Teva Investigational Site 40063, Helsinki

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY